<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840748</url>
  </required_header>
  <id_info>
    <org_study_id>HEALTH-F5-2012-305495-OT4</org_study_id>
    <nct_id>NCT01840748</nct_id>
  </id_info>
  <brief_title>Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schoen Klinik Hamburg Eilbek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Paris 5 - Rene Descartes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of
      the skin and several internal organs.

      Pulmonary hypertension (PH) is a fatal disorder characterized by an increase in pulmonary
      vascular resistance, which leads to right ventricular failure. Despite being recently the
      object of greater attention and despite therapeutic advances, pulmonary hypertension due to
      SSc remains associated with a dismal 47 - 67% 3-year survival. Among SSc patients
      prospectively followed in the &quot;European League Against Rheumatism Scleroderma Trials and
      Research&quot; (EUSTAR) cohort, 26% of death was related to pulmonary hypertension. Although some
      previous data have suggested the protective effects of calcium channel blockers on the
      development of pulmonary hypertension, the potential preventive effects of vasodilators for
      the prevention of Pulmonary hypertension have not been determined yet. In addition to be
      considered routinely for the treatment of SSc-related pulmonary hypertension, prostanoids,
      endothelin receptor antagonists (ETRA) and Phosphodiesterase-5 inhibitors (PDE5i) can also be
      used for this indication.

      This observational trial is one out of five observational trials of the collaborative project
      &quot;To decipher the optimal management of systemic sclerosis&quot; (DeSScipher).

      Aim of this observational trial is:

      - to compare the outcomes of adult and juvenile SSc patients who are at high risk of
      developing pulmonary hypertension and are receiving either different vasodilator treatments
      or no vasodilator treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The number of patients with pulmonary hypertension at 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to development of precapillary pulmonary hypertension</measure>
    <time_frame>2 years</time_frame>
    <description>participants will be followed for the duration of 2 years, the time until development of precapillary pulmonary hypertension is the secondary outcome</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">960</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>no vasodilator</arm_group_label>
    <description>patients receiving no vasodilator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCB</arm_group_label>
    <description>patients receiving a calcium channel blocker (CCB) for digital vasculopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>i.v. prostanoids or PDE5i or ETRAs</arm_group_label>
    <description>patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are adult and juvenile systemic sclerosis patients from the EUSTAR
        cohort (MEDSonline database) and the juvenile systemic sclerosis working group cohort
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Juvenile and adult Systemic sclerosis patients, with diagnosis according to the
             ACR/EULAR adult SSc criteria and PRES/ACR/EULAR juvenile SSc criteria respectively

          -  Patients at high risk of pulmonary hypertension with a Cochin Risk prediction score
             &gt;/= 3

        ACR = American College of Rheumatology; EULAR = European League Against Rheumatism; PRES =
        Pediatric Rheumatology European Society
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick Allanore, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A &amp; INSERM 1016</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Müller-Ladner, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick Allanore, Prof.</last_name>
    <email>yannick.allanore@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérome Avouac, Prof.</last_name>
    <email>javouac@yahoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A &amp; INSERM 1016</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yannick Allanore, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf Müller-Ladner, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingo Tarner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Frerix, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriela Riemekasten, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Pediatric Rheumatology, Klinikum Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Foeldvari, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem - University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7622</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laszlo Czirjak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco Matucci-Cerinic, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico, Via Pansini</name>
      <address>
        <city>Napoli-Italia</city>
        <zip>5-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriele Valentini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Felix-Platter Spital, University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH 4012 Basel</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Walker, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zurich, Department of Rheumatology</name>
      <address>
        <city>Zurich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oliver Distler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Del Galdo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, University College London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Denton, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <last_update_submitted>April 23, 2013</last_update_submitted>
  <last_update_submitted_qc>April 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Paris 5 - Rene Descartes</investigator_affiliation>
    <investigator_full_name>Yannick ALLANORE</investigator_full_name>
    <investigator_title>Prof. Yannik Allanore</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

